ONCOPEPTIDES AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.34 SEK | +14.97% |
|
+12.08% | -56.40% |
| Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
| Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Presentation Operator MessageOperator (Operator)Welcome to Oncopeptides Q4 Report for 2022. [O...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Companyâs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Calendar
2024-05-21
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.40% | 67.6M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ONCO Stock
- News Oncopeptides AB
- Transcript : Oncopeptides AB, 2022 Earnings Call, Feb 16, 2023
